Carilex MedicalROCO:7726 +0.15%34 EBITDA Margin % is -5.50% as of Dec. 2025. GuruFocus rates ROCO:7726 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Carilex Medical ranks worse than 61.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Carilex Medical's EBITDA for the
six
months ended in Dec. 2025 was NT$-10.2 Mil. Carilex Medical's Revenue for the
six
months ended in Dec. 2025 was NT$186.3 Mil. Therefore, Carilex Medical's EBITDA margin for the quarter that ended in Dec. 2025 was -5.50%.
Carilex Medical (ROCO:7726) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Carilex Medical EBITDA Margin % Related Terms
Carilex Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Carilex Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7726 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Carilex Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carilex Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Carilex Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carilex Medical (ROCO:7726) has a EBITDA Margin % of -5.50% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Carilex Medical and its competitors. According to the industry distribution chart, Carilex Medical ranks #506 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 61.9%.
Is Carilex Medical's EBITDA Margin % too high?
Carilex Medical's current EBITDA Margin % is -5.50%. Based on the distribution chart, Carilex Medical ranks #506 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Carilex Medical has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Carilex Medical ranks #506 out of 817 companies for EBITDA Margin %. This places Carilex Medical in the lower half of its industry. The industry median EBITDA Margin % is 7.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Carilex Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carilex Medical's current EBITDA Margin % is -5.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current EBITDA Margin % of -5.50%. The current EBITDA Margin % is -5.50%. Carilex Medical's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current EBITDA Margin % is -5.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
34GF Score
Get the complete analysis for ROCO:7726
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7726 has been successfully added to your 
